Form 4: ANI Pharma Director Sells $1.6M in Shares

ANI Pharmaceuticals Director Thomas Haughey sold 19,341 shares of common stock for approximately $1.66 million, executed under a pre-planned Rule 10b5-1 program.

Summary

• Thomas Haughey, a Director of ANI Pharmaceuticals Inc. (ANIP), sold shares of common stock.
• The transaction occurred on August 12, 2025.
• A total of 19,341 shares were sold.
• The weighted average sales price was $85.93 per share, with individual trade prices ranging from $84.50 to $87.16.
• Following the sale, Thomas Haughey directly owns 36,521 shares of ANIP common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.

Sentiment

Score: 5

Explanation: The filing reports an insider sale, which can be perceived negatively, but the transaction was conducted under a Rule 10b5-1 plan, indicating it was pre-scheduled and not based on new material non-public information, thus mitigating negative sentiment.

Positives

• The transaction was executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-scheduled sale not based on new material non-public information.

Negatives

• A director sold 19,341 shares, reducing their direct ownership in the company.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The director's reduced stake might be viewed with slight caution, though mitigated by the pre-planned Rule 10b5-1 transaction.

Key Dates

Recommendation

The reported transaction is a pre-scheduled sale by a director under a Rule 10b5-1 plan, which suggests the sale is for personal financial planning rather than a reflection of new negative company developments. This type of insider transaction typically does not warrant a change in investment thesis unless combined with other significant company news or a pattern of non-10b5-1 insider selling.

Keywords

ANIP, ANI Pharmaceuticals, insider trading, Form 4, stock sale, director, Thomas Haughey, common stock, Rule 10b5-1